Read by QxMD icon Read

Anemia hematological cancer blood

Daniel R Couriel, Holly Ricker, Mary Steinbach, Catherine J Lee
Neurologic manifestations are common in blood diseases, and they can be caused by the hematologic disorder or its treatment. This article discusses hematologic diseases in adult patients, and categorizes them into benign and malignant conditions. The more common benign hematologic diseases associated with neurologic manifestations include anemias, particularly caused by B12 deficiency and sickle cell disease, and a variety of disorders of hemostasis causing bleeding or thrombosis, including thrombotic microangiopathy...
August 2016: Hematology/oncology Clinics of North America
Kyoko Inadomi, Hozumi Kumagai, Shuji Arita, Nobuhiro Tsuruta, Kotoe Takayoshi, Koji Mishima, Shun-Ichiro Ota, Mamoru Tanaka, Yuta Okumura, Kosuke Sagara, Kenta Nio, Michitaka Nakano, Hiroshi Uchi, Hidetaka Yamamoto, Hiroshi Ariyama, Hitoshi Kusaba, Hiroaki Niiro, Yoshinao Oda, Koichi Akashi, Eishi Baba
BACKGROUND: Anti-programmed cell death 1 antibody nivolumab is a promising agent for various cancers. Immune-related adverse events are recognized; however, bi-cytopenia with nivolumab has not been reported. CASE PRESENTATION: A 73-year-old man was diagnosed with advanced primary malignant melanoma of the esophagus with liver, lung, and lymph node metastases. Previous therapies including dacarbazine and radiation of 39 Gy to the esophageal region were performed, but the liver metastases deteriorated...
July 2016: Medicine (Baltimore)
Saman Shahid
We observed the outcomes of chemotherapy with radiotherapy (CR) or radiotherapy (RT) alone for cancer patients of larynx, breast, blood and brain origins through complete blood count (CBC). Following were more depressed in CR patients: mean corpuscular hemoglobin-MCH & lymphocytes-LYM, hematocrit, mean corpuscular hemoglobin concentration-MCHC, hemoglobin-HB and red blood cells-RBC. In RT patients, following were more depressed: LYM, MCH and MCHC. Overall, in all cancer patients, the lymphocytes were depressed 52%...
September 2016: Critical Reviews in Oncology/hematology
Denise R Nebgen, Helen E Rhodes, Cynthia Hartman, Mark F Munsell, Karen H Lu
OBJECTIVE: To estimate the percentage of women with a hematologic cancer who present with abnormal uterine bleeding (AUB). METHODS: We performed a retrospective analysis of the records of women with hematologic malignancies treated at our institution from January 2002 through January 2016. Women with AUB as the chief presenting symptom were identified. RESULTS: Of the 10,682 women with hematologic malignancies, 38 had AUB as their chief presenting symptom...
August 2016: Obstetrics and Gynecology
Nicholas E Khan, Philip S Rosenberg, Blanche P Alter
Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome associated with high risks of severe bone marrow failure (BMF), acute myeloid leukemia (AML), and solid tumors (ST). Bone marrow transplantation (BMT) provides a theoretical cure for hematologic risks (BMF, AML), but it introduces uncertain risks of transplantation-related mortality (TRM) and carcinogenicity. We developed a mathematical (Markov) decision model to estimate event-free survival (EFS) conditional on age based on per-year cause-specific hazard rates...
October 2016: Biology of Blood and Marrow Transplantation
(no author information available yet)
No abstract text is available yet for this article.
June 2016: Annals of Intensive Care
Jianyang Wang, Yuan Tian, Yuan Tang, Xin Wang, Ning Li, Hua Ren, Hui Fang, Yanru Feng, Shulian Wang, Yongwen Song, Yueping Liu, Weihu Wang, Yexiong Li, Jing Jin
PURPOSE: This study aimed to spare hematopoietical bone marrow (BM) identified by magnetic resonance (MR) radiation in order to alleviate acute hematologic toxicity (HT) for gastric cancer patients treated with postoperative chemoradiotherapy (CRT). METHODS: A prospective, open-label, single-arm Phase II study (; NCT 01863420) was conducted in 25 patients with gastric cancer who were eligible for postoperative concurrent CRT. The MR images of vertebral body T8-L4 were fused with images of simulating computed tomography...
2016: OncoTargets and Therapy
Rocío Vázquez-Sánchez, Raúl Diez-Fernández, Santos Enrech-Frances, Ana Sánchez-Peña, Teresa Molina-García
Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in non-small-cell lung cancer. Some studies have shown that the hemogram on day-8 could be avoided in patients with cisplatin. However, carboplatin had not been studied and is considered to be more myelotoxic than cisplatin. Objective To quantify the incidence of thrombocytopenia, anemia, neutropenia and impaired liver and renal tests on day 8 in patients receiving a doublet protocol including a platinum and vinorelbine...
August 2016: International Journal of Clinical Pharmacy
Mariko Noguchi-Sasaki, Yusuke Sasaki, Yasushi Shimonaka, Kazushige Mori, Kaori Fujimoto-Ouchi
BACKGROUND: Hepcidin, a key regulator of iron metabolism, is produced mainly by interleukin-6 (IL-6) during inflammation. A mechanism linking cancer-related anemia and IL-6 through hepcidin production is suggested. To clarify the hypothesis that overproduction of IL-6 elevates hepcidin levels and contributes to the development of cancer-related anemia, we evaluated anti-IL-6 receptor antibody treatment of cancer-related anemia in an IL-6-producing human lung cancer xenograft model. METHODS: Nude mice were subcutaneously inoculated with cells of the IL-6-producing human lung cancer cell line LC-06-JCK and assessed as a model of cancer-related anemia...
2016: BMC Cancer
David Hong, Jeffrey Infante, Filip Janku, Suzanne Jones, Ly M Nguyen, Howard Burris, Aung Naing, Todd M Bauer, Sarina Piha-Paul, Faye M Johnson, Razelle Kurzrock, Lisa Golden, Scott Hynes, Ji Lin, Aimee Bence Lin, Johanna Bendell
PURPOSE: The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy. PATIENTS AND METHODS: This phase I, nonrandomized, open-label, dose-escalation trial used a 3 + 3 dose-escalation scheme and included patients with advanced solid tumors. Intravenous LY2606368 was dose escalated from 10 to 50 mg/m(2) on schedule 1 (days 1 to 3 every 14 days) or from 40 to 130 mg/m(2) on schedule 2 (day 1 every 14 days)...
May 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
P Franco, R Ragona, F Arcadipane, M Mistrangelo, P Cassoni, N Rondi, M Morino, P Racca, U Ricardi
PURPOSE: This study aimed at investigating whether the irradiated volume of pelvic bone marrow (PBM) and specific subsites may predict the occurrence of acute hematologic toxicity (HT) in anal cancer patients undergoing concurrent chemo-radiation. METHODS: 50 patients, submitted to IMRT and concurrent chemotherapy, were analyzed. Several bony structures were defined on planning-CT: PBM and lumbar-sacral (LSBM), lower pelvis (LPBM) and iliac (IBM) bone marrow. On dose-volume histograms, dosimetric parameters were taken...
April 1, 2016: Clinical & Translational Oncology
Tilman Steinmetz, Jan Schröder, Margarete Plath, Hartmut Link, Michèle Vogt, Melanie Frank, Norbert Marschner
The aim of this prospective cohort study was to assess current antianemic treatment of cancer patients in German routine practice, including diagnostics, treatments, and quality of life (QoL). 88 study sites recruited 1018 patients at the start of antianemic treatment with hemoglobin (Hb) levels <11 g/dL (females) or <12 g/dL (males). Patients were followed up for 12 weeks. 63% of the patients had inoperable solid tumors, 22% operable solid tumors, and 15% hematological malignancies. Over 85% received chemotherapy...
2016: Anemia
Irwin Gross, Kevin M Trentino, Astrid Andreescu, Rhonda Pierson, Richard A Maietta, Shannon Farmer
BACKGROUND: Patient blood management (PBM) programs are associated with reduced transfusion usage, reduced hospital costs, and improved patient outcomes. The application of PBM principles in patients with malignant disease might achieve similar results. However, this population presents unique challenges. The aim of the present study was to investigate the impact of a PBM program on blood usage and patient outcomes in cancer patients, particularly in the setting of restricted use of erythropoiesis-stimulating agents (ESAs)...
March 2016: Oncologist
Ravi A Madan, Fatima H Karzai, Yang-Min Ning, Bamidele A Adesunloye, Xuan Huang, Nancy Harold, Anna Couvillon, Guinevere Chun, Lisa Cordes, Tristan Sissung, Shaunna L Beedie, Nancy A Dawson, Marc R Theoret, David G McLeod, Inger Rosner, Jane B Trepel, Min-Jung Lee, Yusuke Tomita, Sunmin Lee, Clara Chen, Seth M Steinberg, Philip M Arlen, James L Gulley, William D Figg, William L Dahut
OBJECTIVE: To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone. PATIENTS AND METHODS: Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomide with bevacizumab (15 mg/kg), docetaxel (75 mg/m(2) ) and prednisone (10 mg daily). Docetaxel and bevacizumab were administered on day 1 of a 3-week treatment cycle...
October 2016: BJU International
Matthew P Deek, Brian Benenati, Sinae Kim, Ting Chen, Inaya Ahmed, Wei Zou, Joseph Aisner, Salma K Jabbour
PURPOSE: To determine the relationships between radiation doses to the thoracic bone marrow and declines in blood cell counts in non-small cell lung cancer (NSCLC) patients treated with chemoradiation therapy (CRT). METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. Dose-volume histogram (DVH) parameters for the thoracic vertebrae (TV), sternum, scapulae, clavicles, and ribs were assessed for associations with changes in blood counts during the course of CRT...
January 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Jiřina Martínková, Milan Bláha, Ondřej Kubeček, Jana Maláková, Jiří Špaček, Jan Bezouška, Iva Selke Krulichová, Stanislav Filip
PURPOSE: To examine the removal of pegylated liposomal doxorubicin (PLD) during plasmafiltration (PF) and determine whether the drug could be withheld prior to its organ distribution responsible for mucocutaneous toxicity. METHODS: Six patients suffering from platinum-resistant ovarian cancer were treated with a 1-h IV infusion 50 mg/m(2) of PLD/cycle-for three cycles q4w. Over 44 (46)-47(49) h postinfusion, five patients (14 cycles in total) underwent PF using a cascade PF method consisted of plasma separation by centrifugation and plasma treatment using filtration based one volume of plasma treatment, i...
February 2016: Cancer Chemotherapy and Pharmacology
Jaclyn S Knibbe-Hollinger, Natasha R Fields, Tammy R Chaudoin, Adrian A Epstein, Edward Makarov, Sidra P Akhter, Santhi Gorantla, Stephen J Bonasera, Howard E Gendelman, Larisa Y Poluektova
Humanized mice are frequently utilized in bench to bedside therapeutic tests to combat human infectious, cancerous and degenerative diseases. For the fields of hematology-oncology, regenerative medicine, and infectious diseases, the immune deficient mice have been used commonly in basic research efforts. Obstacles in true translational efforts abound, as the relationship between mouse and human cells in disease pathogenesis and therapeutic studies requires lengthy investigations. The interplay between human immunity and mouse biology proves ever more complicated when aging, irradiation, and human immune reconstitution are considered...
2015: Biology Open
Patrick T McGann, Léon Tshilolo, Brigida Santos, George A Tomlinson, Susan Stuber, Teresa Latham, Banu Aygun, Stephen K Obaro, Peter Olupot-Olupot, Thomas N Williams, Isaac Odame, Russell E Ware
BACKGROUND: Sickle cell anemia (SCA) is an inherited hematological disorder that causes a large but neglected global health burden, particularly in Africa. Hydroxyurea represents the only available disease-modifying therapy for SCA, and has proven safety and efficacy in high-resource countries. In sub-Saharan Africa, there is minimal use of hydroxyurea, due to lack of data, absence of evidence-based guidelines, and inexperience among healthcare providers. PROCEDURE: A partnership was established between investigators in North America and sub-Saharan Africa, to develop a prospective multicenter research protocol designed to provide data on the safety, feasibility, and benefits of hydroxyurea for children with SCA...
January 2016: Pediatric Blood & Cancer
Shuji Isotani, Akira Horiuchi, Masayuki Koja, Takahiro Noguchi, Shouichiro Sugiura, Hirofumi Shimoyama, Yasuhiro Noma, Kousuke Kitamura, Toshiyuki China, Shino Tokiwa, Keisuke Saito, Masaki Kimura, Shin-ichi Hisasue, Hisamitsu Ide, Satoru Muto, Raizo Yamaguchi, Shigeo Horie
BACKGROUND: Autoimmune hemolytic anemia (AIHA) is hemolytic anemia characterized by autoantibodies directed against red blood cells. AIHA can be induced by hematological neoplasms such as malignant lymphoma, but is rarely observed in the urological field. We report a case of renal urothelial cancer inducing Coombs-positive warm AIHA and severe thrombocytopenia that was responsive to nephroureterectomy. CASE PRESENTATION: A 52-year-old man presented with a 1-month history of general weakness and dizziness...
2015: BMC Urology
Yang Zhou, Yan Xu, Jing Zhao, Wei Zhong, Mengzhao Wang
BACKGROUND: Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) should be treated with first-line and second-line chemotherapy or target therapy according to the lung cancer guidelines. However, no recommended treatments are available after failure to these treatments. In our study, the efficacy and safety of combined chemotherapy of vinorelbine and ifosfamide as third-line therapy or beyond for advanced NSCLC was evaluated. METHODS: A total of 41 patients took a combination of vinorelbine and ifosfamide as third-line or above chemotherapy in Peking Union Hospital between May 2010 and May 2014...
June 2015: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"